Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million
October 13, 2020 06:59 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension)...
Flexion Therapeutics to Present at the 2020 Cell & Gene Virtual Meeting on the Mesa
October 08, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Adam Muzikant, Ph.D., Senior Vice President, Business Development, will present at...
Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting
October 05, 2020 09:00 ET
|
Flexion Therapeutics, Inc.
Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock...
Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference
September 09, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial
September 08, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
Five patients treated in first cohort of Phase 1 clinical trial evaluating the safety and tolerability of FX201; Drug Monitoring Committee (DMC) supported the initiation of the next dosing cohort ...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 13,940 restricted stock...
Flexion Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference
September 03, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors
August 19, 2020 09:00 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data...
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 25,315 restricted stock...